Suppression Of Uveitis By A STAT3 Single Domain Antibody
Summary:
The National Eye Institute seeks research co-development partners and/or licensees for a STAT3 antibody that can suppress uveitis.
Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a set of Chimeric Antigen Receptors (CARs) that target the γδ T-Cell Receptor.
Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy
Summary:
The National Cancer Institute (NCI) seeks capable licensees interested in commercializing T cell receptor (TCR)-engineered T cells expressing murine/human hybrid receptors.
Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof
Summary:
The National Cancer Institute (NCI) and Frederick National Laboratory for Cancer Research (FNLCR) seek research co-development partners and/or licensees for commercial development of a novel liquid biopsy diagnostic for non-invasive detection of cell-free HPV 6 and 11 DNA for recurrent respiratory papillomatosis (RRP).
Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s)
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for development of papilloma-infiltrating lymphocytes (PIL) as treatment for patients with chronic human papillomavirus (HPV) 6 or 11 infections.
Soluble Antigen-Based ELISA for the Detection of B. malayi Infections
The technology presented is a breakthrough in the diagnosis of lymphatic filariasis, specifically targeting the B. malayi pathogen. It encompasses a novel soluble antigen extract used in both IgG and IgG4-based ELISA tests, aimed at detecting the presence of the filarial infection. This innovation serves as a cornerstone for a CLIA-certified reference test, established and utilized in Dr. Nutman's laboratory since the late 1980s.
Recombinant LL-SXP-1 and Plasmid Encoding LL-SXP-1 for the Immunodiagnosis of Loa Loa
A Loa loa specific antigen that can be used as the basis of an immunoassay for the diagnosis of Loa loa infection.
Polyclonal and Monoclonal Antibodies to Human Eosinophil Major Basic Protein, Eosinophil Peroxidase, Eosinophil Cationic Protein, and Eosinophil-Derived Neurotoxin
Reagents particularly useful in configuring multiplex assays for simultaneous measurement and quantification of multiple eosinophil granule proteins and for immunohistochemistry. Ultimately these reagents may be used as diagnostics for many eosinophil-mediated disorders.
Antigens for Use in Loa Loa Microfilariae Quantitative Immunoassays
Loa loa microfilarial-specific peptide sequences that could be used as a research material as well as for development of immunoassays for detection of Loa loa microfilaremia.
Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21
This invention includes methods for treating or ameliorating fibrosis by inhibiting the interaction between IL-21 Receptor (IL-21R) and IL-21 using either anti-IL-21R monoclonal antibodies (or binding fragments of anti-IL-21R mAbs), anti-IL-21 monoclonal antibodies (or binding fragments of anti-IL-21 mAbs) or soluble IL-21R (or binding fragments of IL-21R). It is believed that the TH2 immune response, induced by IL-21, plays a major role in the in the pathogenesis of tissue fibrosis.